


Claims:

1. A compound of formula (1):



5

wherein:

- Y is a linking group -C(O)- or -S(O)₂-;
- 10 n is zero or the integer 1;
- m is the integer 1, 2, 3 or 4;
- p is the integer 1, 2, 3 or 4;
- R^d is an -OH, -(Alk²)OH (where Alk² is a straight or branched C₁₋₄ alkylene chain), -OR¹ (where R¹ is a straight or branched C₁₋₆ alkyl group), -(Alk²)OR¹,
- 15 -NR²R³ (where R² and R³ may be the same or different and is each independently a hydrogen atom or a straight or branched C₁₋₆ alkyl group), -(Alk²)NR²R³ or straight or branched C₁₋₆ alkyl group;
- Alk¹ is a straight or branched C₁₋₄ alkylene chain;
- Cy¹ is an optionally substituted cycloaliphatic, aromatic or heteroaromatic
- 20 group; and
- Ar is an optionally substituted aromatic or heteroaromatic group;
- and the salts, solvates, hydrates and N-oxides thereof.

2. A compound as claimed in claim 1 wherein R^d is -OH, -(Alk²)OH, -(Alk²)OR¹, -NR²R³ or -(Alk²)NR²R³, in which Alk², R¹, R² and R³ are as
- 25 defined in claim 1.

3. A compound as claimed in claim 1 or claim 2 wherein Alk^2 is $-\text{CH}_2-$ or $-\text{C}(\text{CH}_3)_2-$.
- 5 4. A compound as claimed in any one of the preceding claims wherein R^1 is methyl.
5. A compound as claimed in any one of the preceding claims wherein R^2 is hydrogen or methyl.
- 10 6. A compound as claimed in any one of the preceding claims wherein R^3 is hydrogen or methyl.
7. A compound as claimed in any one of the preceding claims wherein
- 15 Cy^1 is phenyl, fluorophenyl, chlorophenyl, methylphenyl or cyclopropyl.
8. A compound as claimed in any one of the preceding claims wherein Ar is phenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, chlorophenyl, cyanophenyl or methylphenyl.
- 20 9. A compound as claimed in claim 1 as herein specifically disclosed in any one of the Examples.
10. A pharmaceutical composition comprising a compound of formula (1)
- 25 as defined in claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or *N*-oxide thereof, in association with a pharmaceutically acceptable carrier.
11. The use of a compound of formula (1) as defined in claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or *N*-oxide thereof, for the
- 30 manufacture of a medicament for the treatment and/or prevention of a disorder for which an inhibitor of p38 MAP kinase is indicated.

12. A method for the treatment and/or prevention of a disorder for which an inhibitor of p38 MAP kinase is indicated, which comprises administering to a patient in need of such treatment a compound of formula (1) as defined in
5 claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or *N*-oxide thereof.